Abstract：
BACKGROUND: A nano drug delivery system is an effective tool for drug delivery and controlled release, which is used for a variety of medical applications. In recent decades, nano drug delivery systems have been significantly developed with the emergence of new nanomaterials and nanotechnologies.
OBJECTIVE: This article aimed to provide insight into the technological development of nano drug delivery systems through patent analysis.
METHODS: 3708 patent documents were used for patent analysis after retrieval from the Incopat patent database.
RESULTS: The number of patents on nano drug delivery systems has shown a rapid growth trend in the past two decades. At present, China and the United States have obvious contributions to the number of patents. According to the patent data, the nanomaterials used in nano drug delivery system are mainly inorganic nanomaterials, lipid-based nanomaterials, and macromolecules. In recent years, the highly cited patents (≥14) for nano drug delivery systems mainly involve lipid-based nanomaterials, indicating that their technology is mature and widely used. The inorganic nanomaterials in drug delivery have received increasing attention, and the number of related patents has increased significantly after 2016. The number of highly cited patents in the United States is 250, which is much higher than in other countries.
CONCLUSIONS: Even after decades of development, nano drug delivery systems remain a hot topic for researchers. The significant increase in patents since 2016 can be attributed to the large number of new patents from China. However, according to the proportion of highly cited patents in total, China\'s patented technologies in nano drug delivery systems are not advanced enough compared to developed countries, including the United States, Canada, Germany, and France. In the future, research on emerging nanomaterials for nano drug delivery systems, such as inorganic nanomaterials, may focus on developing new materials and optimising their properties. The lipid-based and polymer- based nanomaterials can be continuously improved for the development of new nanomedicines.
OBJECTIVE: This article aimed to provide insight into the technological development of nano drug delivery systems through patent analysis.
METHODS: 3708 patent documents were used for patent analysis after retrieval from the Incopat patent database.
RESULTS: The number of patents on nano drug delivery systems has shown a rapid growth trend in the past two decades. At present, China and the United States have obvious contributions to the number of patents. According to the patent data, the nanomaterials used in nano drug delivery system are mainly inorganic nanomaterials, lipid-based nanomaterials, and macromolecules. In recent years, the highly cited patents (≥14) for nano drug delivery systems mainly involve lipid-based nanomaterials, indicating that their technology is mature and widely used. The inorganic nanomaterials in drug delivery have received increasing attention, and the number of related patents has increased significantly after 2016. The number of highly cited patents in the United States is 250, which is much higher than in other countries.
CONCLUSIONS: Even after decades of development, nano drug delivery systems remain a hot topic for researchers. The significant increase in patents since 2016 can be attributed to the large number of new patents from China. However, according to the proportion of highly cited patents in total, China\'s patented technologies in nano drug delivery systems are not advanced enough compared to developed countries, including the United States, Canada, Germany, and France. In the future, research on emerging nanomaterials for nano drug delivery systems, such as inorganic nanomaterials, may focus on developing new materials and optimising their properties. The lipid-based and polymer- based nanomaterials can be continuously improved for the development of new nanomedicines.
摘要：
背景：纳米药物递送系统是药物递送和控释的有效工具，用于各种医疗应用。近几十年来,随着新纳米材料和纳米技术的出现，纳米药物递送系统得到了显著发展。
目的：本文旨在通过专利分析，为纳米药物递送系统的技术发展提供见解。
方法:在从Incopat专利数据库检索后,将3708专利文献用于专利分析。
结果：在过去的二十年中，纳米药物递送系统的专利数量呈快速增长趋势。目前,中国和美国在专利数量上有明显的贡献。根据专利数据,纳米给药系统中使用的纳米材料主要是无机纳米材料,基于脂质的纳米材料，和大分子。近年来,纳米药物递送系统的高引用专利(≥14)主要涉及基于脂质的纳米材料，表明他们的技术已经成熟和广泛应用。无机纳米材料在药物传递中的应用日益受到重视,2016年后，相关专利数量大幅增加。美国的高引用专利数量为250，远高于其他国家。
结论：即使经过几十年的发展，纳米药物递送系统仍然是研究人员的热门话题。自2016年以来专利的大幅增长可以归因于来自中国的大量新专利。然而,根据高引用专利在总专利中的比例，我国在纳米给药系统方面的专利技术与发达国家相比还不够先进,包括美国,加拿大,德国,和法国。在未来,用于纳米药物递送系统的新兴纳米材料的研究，如无机纳米材料，可以专注于开发新材料和优化其性能。可以持续改进基于脂质和基于聚合物的纳米材料以用于开发新的纳米药物。
目的：本文旨在通过专利分析，为纳米药物递送系统的技术发展提供见解。
方法:在从Incopat专利数据库检索后,将3708专利文献用于专利分析。
结果：在过去的二十年中，纳米药物递送系统的专利数量呈快速增长趋势。目前,中国和美国在专利数量上有明显的贡献。根据专利数据,纳米给药系统中使用的纳米材料主要是无机纳米材料,基于脂质的纳米材料，和大分子。近年来,纳米药物递送系统的高引用专利(≥14)主要涉及基于脂质的纳米材料，表明他们的技术已经成熟和广泛应用。无机纳米材料在药物传递中的应用日益受到重视,2016年后，相关专利数量大幅增加。美国的高引用专利数量为250，远高于其他国家。
结论：即使经过几十年的发展，纳米药物递送系统仍然是研究人员的热门话题。自2016年以来专利的大幅增长可以归因于来自中国的大量新专利。然而,根据高引用专利在总专利中的比例，我国在纳米给药系统方面的专利技术与发达国家相比还不够先进,包括美国,加拿大,德国,和法国。在未来,用于纳米药物递送系统的新兴纳米材料的研究，如无机纳米材料，可以专注于开发新材料和优化其性能。可以持续改进基于脂质和基于聚合物的纳米材料以用于开发新的纳米药物。
